Global Glioblastoma Multiforme (GBM) Treatment Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

Chapter 1 Preface
1.1 Report Description

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Glioblastoma Multiforme Treatment Market (2014 and 2026)
2.2 Global Glioblastoma Multiforme Treatment Market, by Drug, 2016 (USD Million)
2.3 Comparative Analysis: Glioblastoma Multiforme Treatment Market, by Geography, 2016 and 2026 (Value %)

Chapter 3 Market Overview
3.1 Introduction and Market Definition
3.2 Disease Overview
3.2.1 Subtypes of Glioblastoma Multiforme
3.2.1.1 Signatures and Clinical features of GBM subtypes
3.2.2 Epidemiology
3.2.3 Standard treatment options and alternative therapeutics approaches
3.3 Nucleic Acid Delivery Methods
3.3.1 Virus-based
3.3.2 Nonviral-based
3.3.3 Stem cells
3.4 In Vivo Identification of GBM for Diagnostic Implication
3.4.1 Magnetic Resonance Imaging (MRI)
3.4.2 Computed Tomography (CT)
3.4.3 Positron Emission Tomography (PET)
3.4.4 Others
3.5 Biomolecule delivery systems
3.5.1 For Glioblastoma
3.5.1.1 Example of homing targets, polymeric coatings, nanoparticle configurations, and therapeutic agents utilized in nanoparticle drug delivery for glioma
3.5.2 For other Central Nervous System (CNS) disorders
3.6 Market Dynamics
3.6.1 Drivers
3.6.1.1 Rising geriatric population will drive the GBM treatment market as they are more prone to cause GBM
3.6.1.2 Global Rate of Aging Population
3.6.1.3 Various government and non-government organizations are creating worldwide awareness against GBM
3.6.1.4 The future of glioblastoma treatment market expects introduction of several novel therapies due to its strong pipeline
3.6.2 Restraints
3.6.2.1 GBM is highly resistant to DNA modifying agents hence available therapies have limitations
3.6.2.2 The overall survival period delivered by current FDA approved treatments is less
3.6.3 Opportunities
3.6.3.1 Development of immunotherapy and biological therapy treatments along with novel drug delivery systems add advantage over the current conventional treatments
3.7 Event Impact Analysis
3.8 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2015 – 2026 (USD Million)
3.8.1 Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs, 2015 – 2026 (USD Million)
3.8.2 Bevacizumab (Avastin)
3.8.2.1 Global Bevacizumab Market Revenue, 2015 - 2026 (USD Million)
3.8.3 Temozolomide
3.8.3.1 Global Temozolomide Market Revenue, 2015 - 2026 (USD Million)
3.8.4 Carmustine (BiCNU)
3.8.4.1 Global Carmustine (BiCNU) Market Revenue, 2015 - 2026 (USD Million)
3.9 Global Glioblastoma Treatment Market Revenue and Forecast, by Geography, 2015 – 2026 (USD Million)
3.9.1 North America
3.9.1.1 North America Glioblastoma Treatment Market Revenue, 2015 - 2026 (USD Million)
3.9.2 Europe
3.9.2.1 Europe Glioblastoma Treatment Market Revenue, 2015 - 2026 (USD Million)
3.9.3 Asia Pacific
3.9.3.1 Asia Pacific Glioblastoma Treatment Market Revenue, 2015 - 2026 (USD Million)
3.9.4 Rest of the World (RoW)
3.9.4.1 Rest of the World Glioblastoma Treatment Market Revenue, 2015 - 2026 (USD Million)
3.10 Competitive Landscape
3.10.1 Global Glioblastoma Treatment Market: Market Share, by Key Players 2016 (%)

Chapter 4 Global Pipeline Review of Glioblastoma Treatment
4.1 Overview
4.2 Pipeline Analysis : Types of Therapies
4.2.1 Targeted Therapy
4.2.1.1 TRC-105
4.2.2 Gene Therapy
4.2.2.1 VB-111
4.2.2.2 TOCA 511
4.2.3 Immunotherapy
4.2.3.1 DCVax-Brain
4.2.3.2 Rindopepimut (CDX-110)
4.2.3.3 Phase II (ACT II, ACT III and ACTIVATE) trial results of Rindopepimut
4.2.3.4 ICT-107
4.2.3.5 Trivax (AV00113)
4.3 Phase I and II Drug Entities

Chapter 5 Recommendations
5.1 Market Strategy for Success
5.1.1 Focus on the development of immunotherapy and biological therapy treatments
5.1.2 Development of novel drug delivery system (NDDS)
5.1.3 Expected intense competition in the near future

Chapter 6 Company Profiles
6.1 AbbVie, Inc.
6.1.1 Company Overview
6.1.2 Financial Overview
6.1.3 Product Portfolio
6.1.4 Business Strategies
6.1.4.1 Acquisitions and partnership for market penetration
6.1.5 Recent Developments
6.2 Activartis GmbH
6.2.1 Company Overview
6.2.2 Financial Overview
Being a privately owned company, the financial results of Activartis Biotech GmbH is not available in the public domain.
6.2.3 Product Portfolio
6.2.4 Business Strategies
6.2.4.1 Strong focus on research and development
6.2.5 Recent Developments
6.3 Agenus Inc.
6.3.1 Company Overview
6.3.2 Financial Overview
6.3.3 Product Portfolio
6.3.4 Business Strategies
6.3.4.1 Acquisition & Merger
6.3.5 Recent Developments
6.4 Arog Pharmaceuticals, Inc.
6.4.1 Company Overview
6.4.2 Financial Overview
6.4.3 Product Portfolio
6.4.4 Business Strategies
6.4.4.1 Research and development
6.4.5 Acquisition of worldwide rights
6.4.6 Recent Developments
6.5 Bristol-Myers Squibb Company
6.5.1 Company Overview
6.5.2 Financial Overview
6.5.3 Product Portfolio
6.5.4 Business Strategies
6.5.4.1 Acquisitions for company’s growth
6.5.5 Recent Developments
6.6 Cavion LLC
6.6.1 Company Overview
6.6.2 Financial Overview
6.6.3 Product Portfolio
6.6.4 Business Strategies
6.6.4.1 New Drug Development
6.7 Celldex Therapeutics Inc.
6.7.1 Company Overview
6.7.2 Financial Overview
6.7.3 Product Portfolio
6.7.4 Business Strategies
6.7.4.1 Strong Pipeline portfolio
6.7.5 Recent Developments
6.8 CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
6.8.1 Company Overview
6.8.2 Financial Overview
6.8.3 Product Portfolio
6.8.4 Business Strategies
6.8.4.1 Strong Pipeline portfolio
6.8.5 Recent Developments
6.9 Cortice Biosciences Inc.
6.9.1 Company Overview
6.9.2 Financial Overview
6.9.3 Product Portfolio
6.9.4 Business Strategies
6.9.4.1 Acquisition of Exclusive Commercial Rights
6.9.5 Recent Developments
6.10 Eisai Co., Ltd.
6.10.1 Company Overview
6.10.2 Financial Overview
6.10.3 Product Portfolio
6.10.4 Business Strategies
6.10.4.1 Joint Research Agreement
6.10.4.2 Introduction of new lifestyle information website for breast cancer patients
6.10.5 Recent Developments
6.11 Exelixis Inc.
6.11.1 Company Overview
6.11.2 Financial Overview
6.11.3 Product Portfolio
6.11.4 Business Strategies
6.11.4.1 Strong Pipeline portfolio
6.11.4.2 Partnered compounds
6.11.5 Recent Developments
6.12 F. Hoffmann-La Roche Ltd.
6.12.1 Company Overview
6.12.2 Financial Overview
6.12.3 Product Portfolio
6.12.4 Business Strategies
6.12.4.1 Investment in research and development (R&D)
6.12.4.2 Strengthening core business
6.12.4.3 Mergers and Acquisitions
6.12.5 Recent Developments
6.13 Peregrine Pharmaceuticals, Inc.
6.13.1 Company Overview
6.13.2 Financial Overview
6.13.3 Product Portfolio
6.13.4 Business Strategies
6.13.4.1 Licensing agreements and collaborations
6.13.4.2 Research and development approach
6.13.5 Recent Developments
6.14 OncoSynergy
6.14.1 Company Overview
6.14.2 Financial Overview
6.14.3 Product Portfolio
6.14.4 Business Strategies
6.14.5 Recent Developments
6.15 Merrimack Pharmaceuticals, Inc.
6.15.1 Company Overview
6.15.2 Financial Overview
6.15.3 Product Portfolio
6.15.4 Business Strategies
6.15.4.1 Acquisition and collaboration agreement to gain market share
6.15.5 Recent Developments